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Abstract
Graphene oxide (GO) is suggested to have great potential as a component of biomedical devices. 
Although this nanomaterial has been demonstrated to be cytocompatible in vitro, its compatibility 
in vivo in tissue sites relevant for biomedical device application is yet to be fully understood. Here, 
we evaluate the compatibility of GO with two different oxidation levels following implantation in 
subcutaneous and intraperitoneal tissue sites, which are of broad relevance for application to 
medical devices. We demonstrate GO to be moderately compatible in vivo in both tissue sites, with 
the inflammatory reaction in response to implantation consistent with a typical foreign body 
reaction. A reduction in the degree of GO oxidation results in faster immune cell infiltration, 
uptake, and clearance following both subcutaneous and peritoneal implantation. Future work 
toward surface modification or coating strategies could be useful to reduce the inflammatory 
response and improve compatibility of GO as a component of medical devices.
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Potential applications for graphene have been a source of great excitement in the field of 
nanotechnology, as its exceptional mechanical, electronic, and thermal properties1 could 
contribute function as a component in polymer composites,2 electronic devices,3 or 
biomedical devices.4 A preponderance of research on graphenic materials has focused on its 
oxidized state, graphene oxide (GO),5 which is characterized by a high density of carboxylic 
acid, alcohol, and epoxide functional groups.6 Though oxidation compromises the 
electronic7 and mechanical8 properties to an extent, it affords water dispersibility and 
chemical handles for covalent modification.9,10 It is also generally thought that oxidation 
should improve compatibility for biological applications, due to the layer of water associated 
with the hydrophilic functional groups.6,11 As such, GO has generated specific interest for 
use in preparing composite biomaterials,12 photothermal therapies,13–15 imaging 
modalities,16 drug delivery strategies,17,18 and cell-based tissue engineering substrates.19,20
The safety and compatibility of GO in tissue sites relevant for use in medical devices remain 
to be understood. Carbon nanotubes (CNTs), the cylindrical nanocarbon isotope of 
graphene, have been more thoroughly studied than graphene or GO in this regard. However, 
in spite of numerous efforts, no consensus has been reached regarding the safety of CNTs, 
with some studies finding these materials to be genotoxic or carcinogenic21 and others 
finding them to be safe.22 It is anticipated that the meta-stability and water dispersibility of 
GO may offer better prospects for biological compatibility than CNTs. GO is reported to be 
an autodegrading material on the time scale of months, with an aqueous degradation 
pathway resulting in the formation of humic acid.23 This benign end product is the product 
of degradation of all organic matter and may be more easily cleared from the body.
Several studies have evaluated the toxicity of GO in vitro,20,24–28 with a typical conclusion 
that the material is not cytotoxic. It has also been shown that GO may elicit a Toll-like 
receptor-mediated inflammatory response in vitro.29,30 As saying toxicity in vitro does not 
recapitulate the complexities of the physiologic milieu and attendant immune system and 
thus cannot be assumed to be predictive of compatibility in vivo. Like other nanomaterials, 
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the in vivo compatibility of GO remains poorly understood.31 Of the studies that have 
evaluated the toxicity, compatibility, and clearance rates of GO in vivo, most have been 
performed in nonmammalian organisms; genotoxicity has been observed in Caenorhabditis 
elegans,32 but findings in zebrafish suggest that GO is cleared rapidly and has no lasting 
effects.33 In general, it is hypothesized that GO compatibility is governed by the type of 
functionalization34 and its oxidation state.24,33 However, only a few studies have endeavored 
to understand the compatibility of GO in mammals, and like previous work with CNTs, 
there is no consensus in the findings reported. Liu et al. reported that intravenous (IV) 
injection of GO in mice at 10–100 mg/mL induced mutagenesis,35 while Liang et al. have 
reported that IV injection of GO showed no reproductive side effects even at high 
concentrations (25 mg/kg).36 Others report no issues with safety when used in applications 
toward targeted delivery.14,33,34 Efforts to understand the immune response to date have 
included characterization of the acute immune response following intraperitoneal (IP) 
injection.37 Another study has attempted to understand the immune response induced by GO 
after IV injection,38 reporting no systemic pathological changes in mice following 
administration of GO at low concentration. However, this report demonstrated significant 
inflammatory and immune responses when GO was administered at higher concentration 
(>10 mg/kg). To the best of our knowledge, no study has yet characterized the immune 
response when GO is administered by routes relevant for its use as a component in medical 
devices over a time course relevant for characterization of the foreign body reaction.
In this report, we evaluate the compatibility of GO in murine subcutaneous and 
intraperitoneal tissue sites, which are broadly relevant for the development of medical 
devices. In addition, we vary the degree of oxidation for GO to determine if a relationship 
exists between oxidative state and compatibility.
RESULTS AND DISCUSSION
GO used in these studies was synthesized by a modified Hummers method.5 The amount of 
oxidizing reagents used in this synthesis was varied to produce distinct states of GO with 
different C to O ratios. Specifically, GO produced with the traditional stoichiometry gave a 
C to O ratio of 2.8:1 (GO, Supporting Information Figure S1a) and use of less potassium 
permanganate resulted in a form with a C to O ratio of 3.1:1 (GO-R, Supporting Information 
Figure S1b). No trace metal contamination, which could skew compatibility studies, was 
observed in either sample. Further characterization was carried out using X-ray 
photoelectron spectroscopy (XPS, Figure 1a), which showed that both GO and GO-R were 
fully exfoliated, indicated by the disappearance of the graphite d-spacing peak at 3.4 Å in 
the X-ray diffractogram and the appearance of a broad peak at 8.4 Å, characteristic of 
graphene oxide. The oxidation states are further confirmed in the high-resolution scan of the 
carbon peak in XPS (Figure 1b), where the relative intensity of the C–O component 
decreases compared to the C–C component for GO-R versus GO. Similarly in the Fourier 
transform infrared spectroscopy (FTIR) spectra (Figure 1c), the relative intensity of the C=O 
stretch characteristic of the peripheral lactones at 1725 cm−1 in relation to the C=O 
carboxylate peakat 1600cm−1 decreases in GO-R versus GO. Raman spectroscopy was also 
used to characterize the samples (Figure 1d). As expected for a chemically oxidized 
graphenic material, GO and GO-R exist as a broad distribution of multilayer states, 
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suggested by the shape and position of the G peak at 1600 cm−1 and the breadth of the G′ 
2D peak at 2700 cm−1.39 G to D ratios were calculated to be 0.77:1 and 0.78:1 for GO and 
GO-R, respectively. Thermogravimentric analysis (TGA) shows the expected weight loss 
over the range from room temperature to 800 °C of around 40% (Supporting Information 
Figure S2).
We also characterized the solution properties of the material, as this is relevant for 
conditions experienced in vivo, and properties could differ greatly for characterization in the 
dry state compared to an aqueous environment. In solution, the particles of GO and GO-R 
were studied in deionized (DI) water, phosphate buffered saline (PBS), and serum to 
determine if salts and proteins in the body would have any effect on the aggregation state of 
the material. Incidentally, serum caused significant swelling of the GO particles, increasing 
the average particle size from 1110 to 16 200 nm. The size of the GO-R particles remained 
relatively constant at 3500 nm in the presence of PBS and serum (Table 1). Since dynamic 
light scattering (DLS) models may not accurately predict the size of a planar graphene 
particle, we verified these measurements using transmission electron microscopy (TEM) and 
observed a strong correlation for sizes measured in solution by DLS with those observed for 
dried films by TEM (Supporting Information Figure S3). Scanning electron microscopy 
(SEM) showed a consistent morphology for the material regardless of solution conditions or 
oxidation state (Figure 1e,f and Supporting Information Figure S4).
As mentioned, the compatibility of GO has largely been evaluated through an in vitro 
assessment of cytotoxicity. The preponderance of data in these studies has suggested that 
GO is not cytotoxic at moderate concentrations in solution. Therefore, we first sought to 
confirm these findings with the materials prepared here. A microvascular endothelial cell 
line (bEnd.3) and primary murine-derived mesenchymal stem cells were used as model cells 
relevant for applications in medical devices. Using a standard two-color live/dead 
cytotoxicity assay (Figure 2), it was determined that both GO and GO-R exhibited 
cytotoxicity at higher concentrations but were not cytotoxic at concentrations lower than 1 
mg/mL in both cell types. There was a noted effect on cell proliferation at concentrations of 
0.5 mg/mL or higher, as measured by an MTT assay (Supporting Information Figure S5). 
Both GO and GO-R exhibited similar cytotoxicity in these assays, and overall, these studies 
confirmed findings of minimal cytotoxicity at moderate concentrations reported in literature.
Simultaneously, to determine whether interactions with cells and biological components had 
any effect on the properties of graphene oxide, characterization was performed following 
exposure of GO and GO-R to endothelial cells. Qualitatively, the Raman spectra showed 
little change; however, the signal was lower, such that the G to D ratio could no longer be 
calculated with confidence and the G′ 2D peak was obscured (Supporting Information 
Figure S5). The increased noise in the Raman spectra could be a result of proteins adsorbed 
on the surface of GO, which implies that the graphene sheets may not directly interact with 
other cellular materials. To determine if the functional groups were altered following in vitro 
culture, FTIR spectra were collected for GO and GO-R (Supporting Information Figure S6). 
The spectrum of the isolated in vitro milieu was also taken as a control to ensure that any 
peaks observed in the GO or GO-R spectra were not simply due to the presence of 
substances from the cell culture. Significant changes were observed, especially in the nature 
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of the carbonyl peaks. In both GO and GO-R, the C=O signal of the peripheral lactones at 
1725 cm−1 disappeared completely, and the C=O of the carboxylate group at 1600 cm−1 
increased in relative intensity.6 This suggests that in the in vitro conditions, the peripheral 
lactones are opened to give carboxylate groups. An alternative explanation for this shift 
could be a change in pH.40,41 However, the C=O peak is expected to become more 
pronounced at lower pH, suggesting that chemical interaction is a more likely explanation 
for the observed shifts. This offers an explanation to the reported observations that 
functional groups can modulate the compatibility of GO.34
The absence of toxicity in vitro does not necessarily dictate compatibility when a material is 
placed in vivo. The application of materials, such as GO, as medical devices would 
traditionally employ one of the following four routes of administration: (i) intravenous 
injection, (ii) subcutaneous implantation, (iii) intraperitoneal implantation, or (iv) direct 
administration to a specific tissue or organ. For intravenous administration, a general rule is 
that particle size must not exceed the diameter of a capillary (~4–5 μm).42 However, 
nanomaterials that aggregate upon contact with blood may still have the potential to occlude 
pulmonary blood vessels. For the materials prepared here, intravenous administration of both 
GO-R and GO suspended in saline (dosed at either 2 or 20 mg/kg) resulted in lung 
occlusions within 1 min following administration, likely due to particle aggregation and/or 
swelling, like that observed ex vivo in the presence of serum. Hence, tissue compatibility of 
GO through this route of administration was not evaluated further.
Subcutaneous and peritoneal administration of a macroscopic implant is known to elicit a 
classic foreign body response.43 Subcutaneous implants result in a cascade of cellular 
responses that begin with recruitment of neutrophils followed bymonocytes.43,44 These 
white blood cells secrete a variety of cytokines and chemokines, soluble immune-
modulating signaling molecules, that result in the establishment of an inflammatory 
microenvironment at the interface of tissue and implant. In this microenvironment, 
monocytes differentiate into inflammatory macrophages, recruit fibroblasts, and form 
foreign body giant cells to encapsulate the implant.43 Subcutaneous implantation through 
transcutaneous injection of GO or GO-R (20 mg/kg in 100 μL of saline) resulted in the 
formation of a coalesced mass of particles that resembled a macroscopic implant (Figure 3). 
As a result, we observe a classical macroscopic foreign body response against GO and GO-
R when implanted subcutaneously. When comparing GO-R and GO upon excision of the 
implant and adjacent subcutaneous tissue, it was noted that the apparent size of the GO-R 
implant was considerably smaller in volume than that for GO, even though the implantation 
mass and volume were the same. There was also histological evidence of differences in these 
materials, as GO-R appeared to be more aggregated, while GO was more dispersed with the 
appearance of being hydrated. This is consistent with the solution properties of GO relative 
to GO-R in serum ex vivo (DLS and TEM), where considerable swelling was observed in a 
physiologic protein milieu. However, the tissue—material interface for both GO-R and GO 
had the appearance of a macroscopic device, and thus this interface was monitored over time 
in a manner consistent with routine biomedical device evaluation.
At 3 days following subcutaneous implantation, moderate monocyte infiltration was 
observed at the implant interface (Figure 3 and Supporting Information Figure S8). 
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Infiltrating cells resulted in some observed damage and disorganization in the subcutaneous 
muscle tissue. When comparing GO-R to GO, there was a visible increase in monocyte 
presence at the interface for the GO-R samples. Substantial infiltration of monocytes within 
the GO-R macrostructure was also evident at this first time point, whereas GO remained 
primarily uninfiltrated. At both 7 and 14 days following implant, the margins of the GO 
macrostructure had begun to be infiltrated, and though some monocytes were still present, 
the majority of cells at this time were fibroblasts and macrophages. However, inflammatory 
cells had yet to penetrate throughout the material. Conversely, at both 7 and 14 days, GO-R 
was completely infiltrated with macrophages and fibroblasts. In both cases, the infiltrated 
material showed evidence of cell uptake and clearance. In both GO and GO-R, uptake was 
primarily by macrophages, with some evidence of multinucleated giant cells in each case. 
Additionally, clusters of GO-R exhibited some signs of mildfibrosis at 14 days postimplant, 
evident by diffuse staining of large aggregates using Mason’s Trichrome staining 
(Supporting Information Figure S9). It is especially noteworthy that, by day 14, there were 
no signs of inflammation in the adjacent tissue, as subcutaneous muscle, adipose, and fascia 
layers appeared normal by histology with no increased presence of inflammatory cells. One 
month following implantation, GO was mostly infiltrated by macrophages, fibroblasts, and 
giant cells. GO-R remained completely infiltrated, and there was evidence of clearance and 
healing at the implant site. The implant and adjacent tissue showed signs of extensive 
angiogenesis, as the presence of blood vessels in and at the margins of the implant was 
dramatically increased. There was substantial de novo extracellular matrix production 
surrounding clusters of GO-R, but this matrix did not have fibrotic character, as evidenced in 
the Mason’s Trichrome staining. GO, on the other hand, showed less matrix-specific 
staining, and clusters of GO still appeared more diffuse than GO-R.
In brief, both GO and GO-R demonstrated a canonical foreign body reaction following 
subcutaneous implantation. There was evidence of cell uptake by macrophages and giant 
cells in both cases, as well as indications of material clearance from site of injection. The 
dependence of the observed response on oxidation state may possibly be attributable to the 
differences in hydration of the macroscopic mass of GO particles; specifically, the 
aggregated nature of the GOR particles facilitated more infiltration and interpenetration of 
immune cells, as well as increased uptake by macrophages. Conversely, the more hydrated 
macroscopic implant of GO particles was slower to be infiltrated and phagocytosed. 
Additionally, the nature of the surface functional groups could play a role, as suggested by 
the ex vivo data discussed above.
GO and GO-R were injected IP at the same dose as was administered subcutaneously (20 
mg/kg in 100 μL of saline). At serial time points following administration, a peritoneal 
lavage was performed, and the presence of inflammatory cells was identified and quantified 
using flow cytometry (Supporting Information Figure S10) and compared to a control 
injection of PBS. Macrophage levels were significantly reduced in comparison to the PBS 
control until 2 weeks following administration. In contrast, Ly6C+ monocyte levels were 
significantly elevated in the peritoneal exudate 3 days following GO administration when 
compared to both GO-R and control, which continued until 2 weeks following 
administration (Figure 4A). The increase in monocytes following GO injection correlated 
with an increased functional capacity of peritoneal exudate cells to establish an 
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inflammatory microenvironment, as measured by the increased secretion of inflammatory 
cytokines and chemokines (Figure 4B). Ex vivo cytokine and chemokine secretion levels 
from peritoneal exudate cells, determined using an array method to quantify 32 different 
immune-modulating cytokines and chemokines (Supporting Information Figure S11), 
demonstrated significant differences in the secretion of cytokines and chemokines 
commonly associated with inflammation.45,46 Specifically, cells retrieved from GO-injected 
mice at both 3 and 7 days following implantation secreted significantly greater amounts of 
the inflammatory cytokine subunit IL-12p40 (a component of both IL-12 and IL-23) and 
inflammatory chemokines, monocyte chemotactic protein-1 (MCP-1) and macrophage 
inflammatory protein-1β (MIP-1β), compared to GO-R-injected mice (Figure 4B and 
Supporting Information Table S1). However, there were no significant changes in the 
secretion of IL-12p70 or MIP-1α or in the anti-inflammatory cytokine IL-10. Interestingly, 
significantly lower levels of the cytokine IL-6 was secreted by cells from both GO- and GO-
R-injected mice when compared to control mice. IL-6 is a pleiotropic cytokine that has been 
shown to have protective effects and is known to be secreted by various tissues in the body 
in homeostasis.47,48 Additionally, it is capable of suppressing acute inflammatory responses 
by reducing neutrophil recruitment and altering secretion of other inflammatory 
cytokines.48–50 It is possible that the IL-6 levels observed in mice from our control group are 
normal in the peritoneal cavity and are lowered during acute inflammation resulting from the 
injection of GO or GO-R. Finally, the clearance rate of material from the IP space was 
dependent on oxidation level, with GO-R visibly being cleared faster than GO upon gross 
inspection of the peritoneal exudate (Supporting Information Figure S12). Examination of 
histological sections of the liver and spleen using traditional microscopic techniques showed 
no gross morphological changes in these organs, suggestive of systemic compatibility and a 
lack of acute toxicity (Supporting Information Figure S13).
In summary, intraperitoneal administration of GO and GO-R resulted in a characteristic 
inflammatory response with recruitment of monocytes and increases in inflammatory 
cytokine and chemokine secretion when compared to PBS administration. The reduced 
inflammatory response in response to GO-R when compared to GO administration could 
possibly be a result of the differences in the kinetics of clearance rates from the site of 
injection, which may be related to their surface hydrophilicity and functional groups, as well 
as differences in aqueous dispersibility. GO-R, with reduced surface oxidation, could 
potentially be taken up by infiltrating monocytes51 soon after administration. Similar to the 
effects observed following subcutaneous implantation, the clearance rate of GO is slower, 
resulting in increased accumulation of inflammatory monocytes in the peritoneal exudates.
CONCLUSIONS
We have evaluated the compatibility for GO of two different oxidation levels following 
implantation in subcutaneous and peritoneal tissue sites, which are of broad relevance for 
application to medical devices. Overall, GO was demonstrated to be moderately compatible 
in both tissue sites, eliciting an inflammatory response consistent with a typical foreign body 
reaction. A reduction in the degree of GO oxidation resulted in more rapid immune cell 
infiltration, uptake, and clearance from the injection site following subcutaneous 
implantation. Uptake occurred on the order of weeks and resulted from infiltrating 
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monocytes, macrophages, and multinucleated giant cells. Though the implant had dense 
infiltration of immune cells, the adjacent tissue showed no signs of inflammation or injury as 
a result of GO implantation. Following IP administration, GO with higher oxidation resulted 
in increased accumulation of monocytes and an enhanced pro-inflammatory environment. 
Meanwhile, GO-R was more rapidly cleared from the IP space and demonstrated less 
chronic inflammation.
Future work should focus on ascertaining and controlling the clearance mechanisms to fully 
exploit the potential of this material. Additional work toward covalent modification or 
noncovalent coating of graphene oxide could also promote a reduction in inflammatory 
response and improve its compatibility as a component of medical devices. Nevertheless, a 
foreign body reaction can be expected from any medical device, and the severity of that 
observed here is thought to be acceptable. It is hoped that the information provided through 
these studies, showing a transient cell-mediated immune response and cell uptake, can 
inform the use of graphene oxide as a material for scaffolds, controlled release, and other 
medical applications.
MATERIALS AND METHODS
Preparation and Characterization of Graphene Oxide
Synthesis of GO—In a typical experiment, 5 g of graphite (Alfa Aesar, 325 mesh, 
99.9995% metal basis) was added to 125 mL of concentrated sulfuric acid (H2SO4, 95%) in 
a 1 L open heavy-walled reaction vessel over ice behind a blast shield. These reagents were 
allowed to stir vigorously for 10min, at which point 10 g of fresh potassium permanganate 
(KMnO4) was slowly added over the next 20 min. After the addition was complete, the ice 
bath was removed and the reaction was allowed to warm to room temperature over 30 min. 
At this time, a water bath was added and the reaction was gently heated at 35 °C for an 
additional 2 h. After 2 h, the reaction was quenched via the slow addition of 700 mL of DI 
water, followed by 10 mL of hydrogen peroxide solution (H2O2, 30% in water), followed by 
225 mL of DI water. The quenched dispersion was allowed to stir overnight. On the 
following morning, the solids were collected via centrifugation and the graphene oxide was 
purified via dialysis against DI water for 1 week. The solids were lyophilized to typically 
yield of about 10 g of GO (73.7% C, 26.3% O), which was characterized by FTIR, TGA, 
Raman, SEM, TEM, XPS, DLS, and XRD.
Synthesis of GO-R—The same procedure used to synthesize GO was applied using 5 g of 
graphite and 7.5 g of potassium permanganate. Lyophilization typically yielded about 8 g of 
GO-R (75.6% C, 24.4% O), which was again characterized by FTIR, TGA, Raman, SEM, 
TEM, XPS, DLS, and XRD.
Material Characterization—FTIR spectra were determined using a Nexus model 670 
spectrophotometer using the Omnic software package. TGA was performed using a TA 
Instruments Q50 under nitrogen at a scan rate of 15 °C/min from 50 to 800 °C X-ray 
diffraction was measured using Cu Kα radiation on an Inel CPS 120 position-sensitive 
detector with a XRG 3000 generator using a 20 min collection time. ζ-Potentials and particle 
sizes were measured in water using a Brookhaven Instruments Corporation phase analysis 
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light scattering (PALS) ζ-potential analyzer. All values are an average often 10 s scans. XPS 
spectra were recorded and processed using a Physical Electronics Versaprobe II X-ray 
photoelectron spectrometer. Raman spectra were recorded on a Horiba Lab Ram equipped 
with a 533 nm YAG laser using LabSpec 5 processing software. SEM was performed on 
gold-coated samples using a JEOL 6010LA microscope with a tungsten source and an SEI 
detector. TEM was performed using a FEI Tecnai G2 Spirit TWIN microscope. Samples 
were prepared on lacey carbon or copper grids.
In Vitro Assessment of Cytotoxicity
bEnd.3 and RAW 264.7 were obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (low 
glucose containing L-glutamine and sodium pyruvate, Life Technologies, Grand Island, NY, 
USA) containing 10% fetal bovine serum and 1% antibiotics. Mouse mesenchymal stem 
cells were obtained from Life Technologies (Grand Island, NY, USA) and cultured 
according to the manufacturer’s instructions. To assess cytocompatibility, 100 000 cells were 
plated onto a 48-well cell culture plate, and 48 h later, 500μg of graphene oxide in 100μL of 
PBS was added. Following overnight culture in the presence of GO, cell viability was 
assessed using a two-color live-dead cytotoxicity kit (Life Technologies) using calcien AM 
(live, green) and ethidium homodimer (dead, red) to establish cell viability. Following 
staining, cells were imaged on an EVOS fluorescence microscope. MTT cell proliferation 
assay was purchased from Life Technologies (Grand Island, NY, USA) and performed 
according to manufacturer’s instructions.
In Vivo Assessment of Compatibility
Wild-type 8–10 week old male C57BL/6J mice (Jackson Laboratories) were used in all 
studies. Animal studies were performed in accordance with protocols approved by MIT’s 
committee for animal care and followed all local, state, and federal regulations. Mice were 
housed in MIT’s division of comparative medicine facilities and provided with food and 
water ad libitum.
Graphene oxide solutions in PBS were prepared under sterile conditions. A 20 mg/kg dose 
(which corresponds to approximately 0.5 mg of GO per mouse) or 2 mg/kg dose (which 
corresponds to approximately 0.05 mg of GO per mouse) of GO was administered per 
mouse in 100 μL of PBS, using a 27 gauge, 0.5 cm3 insulin syringe. For subcutaneous 
injections, the back of the mouse was shaved and cleaned using 70% ethanol prior to 
injections. To limit variability between mice, each mouse received a subcutaneous injection 
of PBS, GO, and GO-R at three different sites within the same animal. For intraperitoneal 
injections, each mouse was randomly assigned to receive an injection of one of PBS, GO, or 
GO-R. At desired time points, mice were euthanized and the subcutaneous tissue in and 
around the area of PBS, GO, and GO-R administration was dissected. Tissue was 
immediately transferred to 10% formalin fixative prior to sectioning and staining at the 
Histology Core Facility at MIT. Hematoxylin and eosin or Masson’s Trichrome staining was 
performed on slides containing sectioned tissue, and the stained slides were analyzed using 
an EVOS color microscope (Life Technologies). For peritoneal administration, at desired 
time points, mice were euthanized and the peritoneum was infused with 5 mL of cold PBS. 
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Injected PBS along with peritoneal exudate (containing immune cells) was retrieved, passed 
through a 70 μm filter, and stored on ice prior to further analysis. Cells from peritoneal 
exudate were counted using an automated Countess (Life Technologies) cell counter. 
Counted cells were cultured in a 96-well plate overnight in DMEM media (as above). 
Supernatants from these cultures were collected frozen prior to analysis using a 32-plex 
Bioplex cytokine assay (Bio-Rad, Hercules, CA, USA). Another part of the cells was stained 
with the following antibodies against cell-surface proteins: CD11b (clone M1/70), Ly6G 
(1A8), Ly6C (HK1.4), CD19 (6D5), TCRβ (H57-597), F4/80 (BM8), and CD11c (N418) (all 
from Biolegend, San Diego, CA, USA), in the presence of Fc Block for 20 min at 4 °C. 
Flow cytometry data were collected using a BD LSR-II or BD LSR-Fortessa, and the data 
were analyzed using Flow FlowJo (Tree Star Inc., Ashland, OR, USA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(a) X-ray diffractogram of pure graphite (black), GO-R (orange), and GO (blue). (b) X-ray 
photoelectron spectroscopy of the high-resolution carbon peak showing the increased 
presence of C–O bonded carbon in comparison to C–C bonded carbon in GO (top) versus 
GO-R (botton). (c) Fourier transform infrared spectra of the GO and GO-R showing the 
subtle differences in the proportion of oxygen functionalities arising from the oxidation 
state. (d) Raman spectra of graphite (black), GO-R (orange), and GO (blue) showing the 
polydispersity of layers and oxidation states in both GO-R and GO. G to D ratios were 
calculated to be 1.6:1, 0.78:1, and 0.77:1, respectively. SEM at 1000× of (e) GO and (f) GO-
R cast from phosphate buffered saline solutions showing the exfoliated morphology of the 
material in the dried state.
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Figure 2. 
Representative images showing cytocompatibility of GO and GO-R in bEnd.3 microvascular 
endothelial cells (left) and mouse mesencyhmal stem cells (right) across a range of different 
graphene concentrations in media. Cells are stained with calcien AM (green, viable) and 
ethidium homodimer (red, not viable).
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Figure 3. 
Subcutaneous tissue processed by standard histological methods and stained with 
hematoxylin and eosin (H&E). Representative images of the implant site shown for GO 
(left), GO-R (middle), and PBS (right) at 3 days, 7 days, 14 days, and 1 month.
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Figure 4. 
(A) Composition of cellular infiltrate in the peritoneal cavity following injection of graphene 
oxides. Monocytes and macrophage percentages measured 3 days, 7 days, and 14 days 
postinjection of graphene oxides or PBS; *p < 0.05, **p < 0.01, and ***p < 0.001. Data are 
based on n ≥ 3 and are represented as mean ± SD. (B) Cytokines and chemokines secreted 
by cells of the peritoneal cavity. Amounts secreted by cells upon overnight culture and 
measured using a 32-plex luminex assay, of which 7 cytokines/chemokines are listed here. 
Significant differences in levels of IL-12p40, MCP-1, and MIP-1β were observed. Statistical 
analysis of secreted protein levels is provided in Supporting Information Table S1. Data are 
based on n = 3 and are represented as mean + SD.
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